Allogene cd70
WebJun 5, 2024 · Allogeneic BCMA CAR Ts induced sustained antitumor responses in mice supplemented with human cytokines, and, most importantly, maintained their phenotype … WebJan 11, 2024 · As part of the agreement with Cellectis, Allogene is currently advancing ALLO-316 — a candidate targeting CD70 — in adult patients with advanced or metastatic clear cell renal cell carcinoma.
Allogene cd70
Did you know?
WebMar 14, 2024 · The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T program. Allogene Media/Investor Contact: Christine Cassiano Chief Communications Officer (714) 552-0326 [email protected]. Additional Allogene Media … WebApr 13, 2024 · ALLO-316 targets CD70, which is expressed in a number of malignancies ranging from solid tumors such as RCC, lung cancer and glioblastoma to hematologic …
WebNov 13, 2024 · CD70 is a TNF superfamily member expressed on subsets of activated lymphocytes and is being explored as a CAR T target for renal cell carcinoma but may … WebFeb 16, 2024 · 384 Background: Renal cell carcinoma (RCC) comprises a heterogeneous group of tumors of different histological subtypes. Each subtype is characterized by distinct immunohistochemical and molecular features and different biology. Currently, patients with advanced RCC have poor disease outcomes despite recent breakthroughs in …
WebApr 13, 2024 · Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal Published: Apr 13, 2024 Data Continue to Highlight the Potential of ALLO-316 to Treat Both Solid Tumors and Hematologic … WebNov 29, 2024 · ALLO-316, an AlloCAR T investigational product targets CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors.
WebDec 2, 2024 · 29 Nov 2024 Efficacy and adverse events data from aphase I trial in Renal cell carcinoma released by Allogene Therapeutics. 10 Mar 2024 ALLO 316 receives Fast Track designation for Renal cell carcinoma [Parenteral] (Late-stage disease, Metastatic disease) in USA. 11 Feb 2024 Allogene Therapeutics reinitiates enrolment in phase I TRAVERSE …
WebMar 21, 2024 · CD70 (CD70 Molecule) is a Protein Coding gene. Diseases associated with CD70 include Lymphoproliferative Syndrome 3 and Lymphoma . Among its related … chile atlasWebJul 18, 2024 · CD70 is highly expressed in renal cell carcinoma (RCC), with limited expression in normal tissue, making it an attractive CAR T target for an immunogenic … gp red whale sign inWebNov 13, 2024 · CD70 is a TNF superfamily member expressed on subsets of activated lymphocytes and is being explored as a CAR T target for renal cell carcinoma but may also be suitable for targeting hematological malignancies. gpre earnings callWebThe Asset Team Leader (ATL) position is accountable for developing and driving the Clinical Development strategy in alignment with the overall portfolio strategy of Allogene. This … chile average life expectancy 2021WebOur next two most advanced products are ALLO-715, which targets BCMA for the treatment of r/r Multiple Myeloma and ALLO-316 which targets CD70 and is currently being investigated for the treatment of clear cell renal cell carcinoma. These are just the first in a line of AlloCAR T™ products we plan to develop. gpre earningsWebOct 8, 2024 · Allogene is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. It has a deep pipeline of allogeneic chimeric antigen receptor... gp reduction\\u0027sWebFeb 28, 2024 · CD70 (ALLO-316): Initial Proof-of-Concept for an Allogeneic CAR T in Solid Tumors Published Phase 1 Data from the UNIVERSAL Study of ALLO-715 in Nature Medicine Presented Dagger™ Technology, a Next Generation Allogeneic Platform Designed to Control Rejection of AlloCAR T Cells Ended 2024 with $576 Million in Cash, Cash … gp red whale menopause